What can we do and what should we do from a legal standpoint?

被引:0
|
作者
Hérait, P [1 ]
机构
[1] Cvitkovic & Associes Consultants, F-94278 Le Kremlin Bicetre, France
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:157 / 157
页数:1
相关论文
共 50 条
  • [1] Management of medical risk - What we can, should and must do from a legal standpoint
    Ulsenheimer, K
    Bock, RW
    [J]. ANASTHESIOLOGIE & INTENSIVMEDIZIN, 1996, 37 (03): : 141 - 145
  • [2] What we do, what we should do, and what we should not do
    Ernst, E
    [J]. ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2001, 7 (04) : 36 - +
  • [3] Atrial fibrillation:: What can we do, what should we do, and what must we do?
    Gjesdal, K
    [J]. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2005, 39 (06) : 324 - 326
  • [4] Neurocognitive enhancement: what can we do and what should we do?
    Farah, MJ
    Illes, J
    Cook-Deegan, R
    Gardner, H
    Kandel, E
    King, P
    Parens, E
    Sahakian, B
    Wolpe, PR
    [J]. NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 421 - 425
  • [5] Neurocognitive enhancement: what can we do and what should we do?
    Martha J. Farah
    Judy Illes
    Robert Cook-Deegan
    Howard Gardner
    Eric Kandel
    Patricia King
    Eric Parens
    Barbara Sahakian
    Paul Root Wolpe
    [J]. Nature Reviews Neuroscience, 2004, 5 : 421 - 425
  • [6] Prevention and Pharmacovigilance What Should We Do, What Can We Do?
    Edwards, I. Ralph
    [J]. DRUG SAFETY, 2012, 35 (02) : 87 - 90
  • [7] The Regional Distribution of Rheumatologists: What Can We Do, What Should We Do?
    Deal, Chad L.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3011 - 3013
  • [8] Prevention and PharmacovigilanceWhat Should We Do, What Can We Do?
    I. Ralph Edwards
    [J]. Drug Safety, 2012, 35 : 87 - 90
  • [9] The evaluation of innovation in radiation oncology - what can we do and what should we do?
    Pignol, Jean-Philippe
    Janus, Cecile
    [J]. ACTA ONCOLOGICA, 2015, 54 (09) : 1251 - 1253